learn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
Search
forLearn
4 / 801 resultslearn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Fluridil
a topical anti-androgen with less systemic involvement
Research
5 / 1000+ results
research Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor
Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
research Bicalutamide
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
research Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss
Bicalutamide may be a promising alternative treatment for female pattern hair loss.
Community Join
3 / 1000+ resultscommunity [Research] RU-58841/Pyrilutamide and impacts on male fertility
The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.
community Bicalutamide and muscles growth
A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.
community Binding affinity of pyrilutamide!
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
Experts
— no results
Clinics
— no results